Abstract
BackgroundLemzoparlimab (also known as TJC4) is a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties. Previous data has shown that CD47 is upregulated preferentially in HER2-expressing cells and...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
